265 related articles for article (PubMed ID: 31129353)
21. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
[TBL] [Abstract][Full Text] [Related]
22. Economic and Clinical Burden of Virus-Associated Hemorrhagic Cystitis in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation in the United States.
McGuirk J; Divine C; Moon SH; Chandak A; Zhang Z; Papanicolaou GA
Transplant Cell Ther; 2021 Jun; 27(6):505.e1-505.e9. PubMed ID: 33775616
[TBL] [Abstract][Full Text] [Related]
23. Association of Socioeconomic Status with Chronic Graft-versus-Host Disease Outcomes.
Hamilton BK; Rybicki L; Arai S; Arora M; Cutler CS; Flowers MED; Jagasia M; Martin PJ; Palmer J; Pidala J; Majhail NS; Lee SJ; Khera N
Biol Blood Marrow Transplant; 2018 Feb; 24(2):393-399. PubMed ID: 29032275
[TBL] [Abstract][Full Text] [Related]
24. Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation.
Pallua S; Giesinger J; Oberguggenberger A; Kemmler G; Nachbaur D; Clausen J; Kopp M; Sperner-Unterweger B; Holzner B
Bone Marrow Transplant; 2010 Oct; 45(10):1534-9. PubMed ID: 20228854
[TBL] [Abstract][Full Text] [Related]
25. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
26. Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease.
Vaughn JE; Gooley T; Maziarz RT; Pulsipher MA; Bhatia S; Maloney DG; Sandmaier BM; Flowers ME; Storb R; Sorror ML
Br J Haematol; 2015 Nov; 171(3):411-6. PubMed ID: 26194447
[TBL] [Abstract][Full Text] [Related]
27. Factors Predicting Graft-versus-Host Disease-Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single Center.
Solh M; Zhang X; Connor K; Brown S; Solomon SR; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1403-1409. PubMed ID: 27095692
[TBL] [Abstract][Full Text] [Related]
28. Burden of morbidity in 10+ year survivors of hematopoietic cell transplantation: report from the bone marrow transplantation survivor study.
Sun CL; Kersey JH; Francisco L; Armenian SH; Baker KS; Weisdorf DJ; Forman SJ; Bhatia S
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1073-80. PubMed ID: 23583827
[TBL] [Abstract][Full Text] [Related]
29. Estimating the Lifetime Medical Cost Burden of an Allogeneic Hematopoietic Cell Transplantation Patient.
Maziarz RT; Devine S; Garrison LP; Agodoa I; Badaracco J; Gitlin M; Perales MA
Transplant Cell Ther; 2023 Oct; 29(10):637.e1-637.e9. PubMed ID: 37364775
[TBL] [Abstract][Full Text] [Related]
30. Graft-Versus-Host Disease in Multiple Myeloma Patients Treated With Daratumumab After Allogeneic Transplantation.
Nikolaenko L; Chhabra S; Biran N; Chowdhury A; Hari PN; Krishnan A; Richter J
Clin Lymphoma Myeloma Leuk; 2020 Jun; 20(6):407-414. PubMed ID: 32249196
[TBL] [Abstract][Full Text] [Related]
31. Impact of chronic GVHD on QOL assessed by visual analogue scale in pediatric HSCT survivors and differences between raters: a cross-sectional observational study in Japan.
Hayakawa A; Sato I; Kamibeppu K; Ishida Y; Inoue M; Sato A; Shiohara M; Yabe H; Koike K; Adachi S; Atsuta Y; Yamashita T; Kanda Y; Okamoto S
Int J Hematol; 2022 Jan; 115(1):123-128. PubMed ID: 34601694
[TBL] [Abstract][Full Text] [Related]
32. Long-term survivors demonstrate superior quality of life after haploidentical stem cell transplantation to matched sibling donor transplantation.
Zhang X; Wang J; Liu Y; Liu J; Wang B; Zhang Q; Guan W; Zhang H; Xu L; Liu G; Zhang P; He Y; Feng S; Han M; Li C; Jiang E; Xie W
J Transl Med; 2022 Dec; 20(1):596. PubMed ID: 36517908
[TBL] [Abstract][Full Text] [Related]
33. Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.
Finke J; Schmoor C; Bethge WA; Ottinger H; Stelljes M; Volin L; Heim D; Bertz H; Grishina O; Socie G
Lancet Haematol; 2017 Jun; 4(6):e293-e301. PubMed ID: 28583289
[TBL] [Abstract][Full Text] [Related]
34. Quality of life in 244 recipients of allogeneic bone marrow transplantation.
Chiodi S; Spinelli S; Ravera G; Petti AR; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Frassoni F; Bacigalupo A
Br J Haematol; 2000 Sep; 110(3):614-9. PubMed ID: 10997973
[TBL] [Abstract][Full Text] [Related]
35. Current Graft-versus-Host Disease-Free, Relapse-Free Survival: A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant.
Solomon SR; Sizemore C; Zhang X; Ridgeway M; Solh M; Morris LE; Holland HK; Bashey A
Biol Blood Marrow Transplant; 2017 Jul; 23(7):1208-1214. PubMed ID: 28390985
[TBL] [Abstract][Full Text] [Related]
36. Reducing Treatment-Related Mortality Did Not Improve Outcomes of Allogeneic Myeloablative Hematopoietic Cell Transplantation for High-Risk Multiple Myeloma: A University of Michigan Prospective Series.
Pawarode A; Mineishi S; Reddy P; Braun TM; Khaled YA; Choi SW; Magenau JM; Harris AC; Connelly JA; Kitko CL; Parkin BL; Goldstein SC; Yanik GA; Levine JE; Ferrara JL; Couriel DR
Biol Blood Marrow Transplant; 2016 Jan; 22(1):54-60. PubMed ID: 26211984
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of differences in quality of life in patients with chronic graft-versus-host disease].
Huang SQ; Huang RH; Quan Y; Wang FM; Cheng XJ; Wang XQ; Zhang X
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):54-61. PubMed ID: 38527839
[No Abstract] [Full Text] [Related]
38. Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host Disease.
Kilgour JM; Wali G; Gibbons E; Scherwath A; Barata Badiella A; Peniket A; Schoemans H; Matin RN;
Biol Blood Marrow Transplant; 2020 May; 26(5):e113-e127. PubMed ID: 32028026
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the Impact of Autologous Hematopoietic Stem Cell Transplantation on the Quality of Life of Older Patients with Lymphoma.
Lemieux C; Ahmad I; Bambace NM; Bernard L; Cohen S; Delisle JS; Fleury I; Kiss T; Mollica L; Roy DC; Sauvageau G; Roy J; Lachance S
Biol Blood Marrow Transplant; 2020 Jan; 26(1):157-161. PubMed ID: 31521818
[TBL] [Abstract][Full Text] [Related]
40. Post-Transplant Cyclophosphamide and Tacrolimus-Mycophenolate Mofetil Combination Prevents Graft-versus-Host Disease in Allogeneic Peripheral Blood Hematopoietic Cell Transplantation from HLA-Matched Donors.
Carnevale-Schianca F; Caravelli D; Gallo S; Coha V; D'Ambrosio L; Vassallo E; Fizzotti M; Nesi F; Gioeni L; Berger M; Polo A; Gammaitoni L; Becco P; Giraudo L; Mangioni M; Sangiolo D; Grignani G; Rota-Scalabrini D; Sottile A; Fagioli F; Aglietta M
Biol Blood Marrow Transplant; 2017 Mar; 23(3):459-466. PubMed ID: 28039079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
